Intravesical instillation with live, attenuated Mycobacterium Bacillus Calmette-Guérin (BCG ... criticize the suboptimal monthly maintenance regimen in the BCG arm and the low concentration ...

The bacillus Calmette–Guérin (BCG) vaccine, initially developed to provide protection against TB, also protects against leprosy; and the magnitude of this effect varies. Previous meta-analyses ...

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in ...

Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

Morales’s protocol of 6-weekly intravesical instillations of bacillus Calmette–Guerin (BCG), introduced in 1976, has survived to this date. BCG is superior to chemotherapy as an adjuvant agent ...

Given a global shortage of bacillus Calmette-Guérin (BCG) treatment, it has been important to determine whether there are effective alternatives for intermediate-risk non-muscle-invasive bladder ...

for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary ...

The U.S. Food and Drug Administration (FDA) approved ImmunityBio’s ANKTIVA, an IL-15 agonist immunotherapy, in combination with the Bacillus Calmette ... ANKTIVA with BCG maintenance therapy ...

Pfizer's Phase III CREST trial evaluating sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment with or without maintenance in subjects with BCG-naïve, high-risk non-muscle ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance ... agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment ...